Lannett to commence marketing for generic Adderall XR in coming months
Lannett announced that it expects to commence marketing in the coming months a generic version of Adderall XR, an extended-release mixed salt of a single entity Amphetamine tablet product with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg tablets. Adderall XR including generic versions have an estimated IQVIA market value of approximately $1.3B for the 12 months ending October, although actual generic market values are expected to be lower. In March, Lannett entered into an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive U.S. distributor of certain drug products, including generic Adderall IR and generic Adderall XR. Under the agreement, Lannett primarily provides sales, marketing and distribution support for the products, for which it receives a share of the profits.